Zacks: Brokerages Anticipate Zoetis Inc (ZTS) Will Announce Earnings of $0.77 Per Share

Equities research analysts expect Zoetis Inc (NYSE:ZTS) to announce earnings of $0.77 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $0.75 to $0.79. Zoetis posted earnings per share of $0.69 in the same quarter last year, which suggests a positive year over year growth rate of 11.6%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 21st.

On average, analysts expect that Zoetis will report full year earnings of $3.11 per share for the current year, with EPS estimates ranging from $3.08 to $3.13. For the next year, analysts anticipate that the company will post earnings of $3.46 per share, with EPS estimates ranging from $3.29 to $3.57. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Zoetis.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.46 billion. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.65 EPS.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Wednesday, October 17th. Morgan Stanley set a $100.00 target price on shares of Zoetis and gave the company a “hold” rating in a research note on Friday, November 2nd. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Argus upped their target price on shares of Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a research note on Tuesday, August 14th. Finally, BMO Capital Markets upped their target price on shares of Zoetis to $93.00 and gave the company a “neutral” rating in a research note on Monday, November 12th. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $94.00.

In other Zoetis news, insider Heidi C. Chen sold 2,500 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $93.51, for a total value of $233,775.00. Following the transaction, the insider now directly owns 17,662 shares in the company, valued at $1,651,573.62. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Juan Ramon Alaix sold 150,306 shares of the business’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $94.96, for a total transaction of $14,273,057.76. Following the completion of the transaction, the chief executive officer now owns 246,319 shares in the company, valued at $23,390,452.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 169,511 shares of company stock worth $16,081,299. Company insiders own 0.35% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group lifted its position in shares of Zoetis by 9.7% during the third quarter. Rehmann Capital Advisory Group now owns 2,403 shares of the company’s stock worth $220,000 after purchasing an additional 213 shares in the last quarter. Marshall Wace North America L.P. lifted its position in shares of Zoetis by 32.6% during the third quarter. Marshall Wace North America L.P. now owns 4,202,241 shares of the company’s stock worth $384,757,000 after purchasing an additional 1,034,161 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Zoetis by 76.4% during the third quarter. Marshall Wace LLP now owns 3,216,573 shares of the company’s stock worth $294,509,000 after purchasing an additional 1,393,397 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of Zoetis during the third quarter worth approximately $9,773,000. Finally, Great Lakes Advisors LLC lifted its position in shares of Zoetis by 201.5% during the third quarter. Great Lakes Advisors LLC now owns 48,635 shares of the company’s stock worth $4,453,000 after purchasing an additional 32,502 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

NYSE ZTS opened at $88.09 on Monday. The stock has a market capitalization of $43.44 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 1.78 and a beta of 0.99. Zoetis has a twelve month low of $70.20 and a twelve month high of $96.57. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04.

The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th were given a $0.126 dividend. The ex-dividend date was Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.57%. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Further Reading: Bond

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply